Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Long bone structural proportions and locomotor behavior in Cercopithecidae.

Ruff CB, Harper CM, Goldstein DM, Daegling DJ, McGraw WS.

J Hum Evol. 2019 Jul;132:47-60. doi: 10.1016/j.jhevol.2019.04.003. Epub 2019 May 14.

PMID:
31203851
2.

Increased variation in numbers of presacral vertebrae in suspensory mammals.

Williams SA, Spear JK, Petrullo L, Goldstein DM, Lee AB, Peterson AL, Miano DA, Kaczmarek EB, Shattuck MR.

Nat Ecol Evol. 2019 Jun;3(6):949-956. doi: 10.1038/s41559-019-0894-2. Epub 2019 May 13.

PMID:
31086278
3.

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.

Venetsanakos E, Brameld KA, Phan VT, Verner E, Owens TD, Xing Y, Tam D, LaStant J, Leung K, Karr DE, Hill RJ, Gerritsen ME, Goldstein DM, Funk JO, Bradshaw JM.

Mol Cancer Ther. 2017 Dec;16(12):2668-2676. doi: 10.1158/1535-7163.MCT-17-0309. Epub 2017 Oct 4.

4.

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.

Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J, Loughhead DG, Ton T, Karr DE, Gerritsen ME, Goldstein DM, Funk JO.

J Med Chem. 2017 Aug 10;60(15):6516-6527. doi: 10.1021/acs.jmedchem.7b00360. Epub 2017 Jul 25.

PMID:
28665128
5.

Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).

Lou Y, Lopez F, Jiang Y, Han X, Brotherton C, Billedeau R, Gabriel S, Gleason S, Goldstein DM, Hilgenkamp R, Kocer B, Orzechowski L, Tan J, Wovkulich P, Wen B, Fry D, Di Lello P, Chen L, Zhang FJ, Fretland J, Nangia A, Yang T, Owens TD.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):632-635. doi: 10.1016/j.bmcl.2016.11.092. Epub 2016 Dec 2.

PMID:
28025004
6.

Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J.

Nat Chem Biol. 2015 Jul;11(7):525-31. doi: 10.1038/nchembio.1817. Epub 2015 May 25.

7.

Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.

Lou Y, Sweeney ZK, Kuglstatter A, Davis D, Goldstein DM, Han X, Hong J, Kocer B, Kondru RK, Litman R, McIntosh J, Sarma K, Suh J, Taygerly J, Owens TD.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):367-71. doi: 10.1016/j.bmcl.2014.11.030. Epub 2014 Nov 20.

PMID:
25466710
8.

James V. Neel and Yuri E. Dubrova: Cold War debates and the genetic effects of low-dose radiation.

Goldstein DM, Stawkowski ME.

J Hist Biol. 2015 Spring;48(1):67-98. doi: 10.1007/s10739-014-9385-0.

PMID:
25001362
9.

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis.

Lou Y, Han X, Kuglstatter A, Kondru RK, Sweeney ZK, Soth M, McIntosh J, Litman R, Suh J, Kocer B, Davis D, Park J, Frauchiger S, Dewdney N, Zecic H, Taygerly JP, Sarma K, Hong J, Hill RJ, Gabriel T, Goldstein DM, Owens TD.

J Med Chem. 2015 Jan 8;58(1):512-6. doi: 10.1021/jm500305p. Epub 2014 Apr 16.

PMID:
24712864
10.

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.

Lucas MC, Bhagirath N, Chiao E, Goldstein DM, Hermann JC, Hsu PY, Kirchner S, Kennedy-Smith JJ, Kuglstatter A, Lukacs C, Menke J, Niu L, Padilla F, Peng Y, Polonchuk L, Railkar A, Slade M, Soth M, Xu D, Yadava P, Yee C, Zhou M, Liao C.

J Med Chem. 2014 Mar 27;57(6):2683-91. doi: 10.1021/jm401982j. Epub 2014 Feb 26.

PMID:
24520947
11.

Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.

Palmer WS, Alam M, Arzeno HB, Chang KC, Dunn JP, Goldstein DM, Gong L, Goyal B, Hermann JC, Hogg JH, Hsieh G, Jahangir A, Janson C, Jin S, Ursula Kammlott R, Kuglstatter A, Lukacs C, Michoud C, Niu L, Reuter DC, Shao A, Silva T, Trejo-Martin TA, Stein K, Tan YC, Tivitmahaisoon P, Tran P, Wagner P, Weller P, Wu SY.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1486-92. doi: 10.1016/j.bmcl.2012.12.047. Epub 2012 Dec 22.

PMID:
23352510
12.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.

Padilla F, Bhagirath N, Chen S, Chiao E, Goldstein DM, Hermann JC, Hsu J, Kennedy-Smith JJ, Kuglstatter A, Liao C, Liu W, Lowrie LE Jr, Luk KC, Lynch SM, Menke J, Niu L, Owens TD, O-Yang C, Railkar A, Schoenfeld RC, Slade M, Steiner S, Tan YC, Villaseñor AG, Wang C, Wanner J, Xie W, Xu D, Zhang X, Zhou M, Lucas MC.

J Med Chem. 2013 Feb 28;56(4):1677-92. doi: 10.1021/jm301720p. Epub 2013 Feb 12.

PMID:
23350847
13.

Rational design of highly selective spleen tyrosine kinase inhibitors.

Lucas MC, Goldstein DM, Hermann JC, Kuglstatter A, Liu W, Luk KC, Padilla F, Slade M, Villaseñor AG, Wanner J, Xie W, Zhang X, Liao C.

J Med Chem. 2012 Dec 13;55(23):10414-23. doi: 10.1021/jm301367c. Epub 2012 Nov 27.

PMID:
23151054
14.

Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.

Murray JM, Sweeney ZK, Chan BK, Balazs M, Bradley E, Castanedo G, Chabot C, Chantry D, Flagella M, Goldstein DM, Kondru R, Lesnick J, Li J, Lucas MC, Nonomiya J, Pang J, Price S, Salphati L, Safina B, Savy PP, Seward EM, Ultsch M, Sutherlin DP.

J Med Chem. 2012 Sep 13;55(17):7686-95. doi: 10.1021/jm300717c. Epub 2012 Aug 21.

PMID:
22877085
15.

Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.

Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, Lesnick J, Lucas MC, Lewis C, Murray J, Nadin AJ, Nonomiya J, Pang J, Pegg N, Price S, Reif K, Safina BS, Salphati L, Staben S, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Ultsch M, Waszkowycz B, Wei B.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4296-302. doi: 10.1016/j.bmcl.2012.05.027. Epub 2012 May 17.

PMID:
22672799
16.

Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.

Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH, Cartwright MW, Castanedo G, Chabot C, Cheguillaume AJ, Goldsmith P, Goldstein DM, Goyal B, Hancox T, Handa RK, Iyer PS, Kaur J, Kondru R, Kenny JR, Krintel SL, Li J, Lesnick J, Lucas MC, Lewis C, Mukadam S, Murray J, Nadin AJ, Nonomiya J, Padilla F, Palmer WS, Pang J, Pegg N, Price S, Reif K, Salphati L, Savy PA, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Tay S, Tivitmahaisoon P, Waszkowycz B, Wei B, Yue Q, Zhang C, Sutherlin DP.

J Med Chem. 2012 Jun 28;55(12):5887-900. doi: 10.1021/jm3003747. Epub 2012 Jun 11.

PMID:
22626259
17.

Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM.

J Med Chem. 2012 May 24;55(10):4539-50. doi: 10.1021/jm300035p. Epub 2012 Mar 21. Review. No abstract available.

PMID:
22394077
18.

3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.

Soth M, Abbot S, Abubakari A, Arora N, Arzeno H, Billedeau R, Dewdney N, Durkin K, Frauchiger S, Ghate M, Goldstein DM, Hill RJ, Kuglstatter A, Li F, Loe B, McCaleb K, McIntosh J, Papp E, Park J, Stahl M, Sung ML, Suttman R, Swinney DC, Weller P, Wong B, Zecic H, Gabriel T.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3452-6. doi: 10.1016/j.bmcl.2011.03.098. Epub 2011 Apr 1.

PMID:
21515047
19.

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.

Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J, Farrell R, Frauchiger S, La Fargue J, Ghate M, Graves B, Hill RJ, Li F, Litman R, Loe B, McIntosh J, McWeeney D, Papp E, Park J, Reese HF, Roberts RT, Rotstein D, San Pablo B, Sarma K, Stahl M, Sung ML, Suttman RT, Sjogren EB, Tan Y, Trejo A, Welch M, Weller P, Wong BR, Zecic H.

J Med Chem. 2011 Apr 14;54(7):2255-65. doi: 10.1021/jm101423y. Epub 2011 Mar 4.

PMID:
21375264
20.

Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors.

Olaharski AJ, Bitter H, Gonzaludo N, Kondru R, Goldstein DM, Zabka TS, Lin H, Singer T, Kolaja K.

Toxicol Sci. 2010 Nov;118(1):266-75. doi: 10.1093/toxsci/kfq258. Epub 2010 Sep 1.

PMID:
20810542
21.

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Goldstein DM, Kuglstatter A, Lou Y, Soth MJ.

J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906. No abstract available.

PMID:
19950901
22.

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.

J Pharmacol Exp Ther. 2008 Dec;327(3):610-9. doi: 10.1124/jpet.108.139006. Epub 2008 Sep 5.

PMID:
18776065
23.

High-throughput kinase profiling as a platform for drug discovery.

Goldstein DM, Gray NS, Zarrinkar PP.

Nat Rev Drug Discov. 2008 May;7(5):391-7. doi: 10.1038/nrd2541. Review.

PMID:
18404149
24.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.

Goldstein DM, Alfredson T, Bertrand J, Browner MF, Clifford K, Dalrymple SA, Dunn J, Freire-Moar J, Harris S, Labadie SS, La Fargue J, Lapierre JM, Larrabee S, Li F, Papp E, McWeeney D, Ramesha C, Roberts R, Rotstein D, San Pablo B, Sjogren EB, So OY, Talamas FX, Tao W, Trejo A, Villasenor A, Welch M, Welch T, Weller P, Whiteley PE, Young K, Zipfel S.

J Med Chem. 2006 Mar 9;49(5):1562-75.

PMID:
16509574
25.

Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.

Goldstein DM, Gabriel T.

Curr Top Med Chem. 2005;5(10):1017-29. Review.

PMID:
16178744
26.

Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.

Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM.

J Med Chem. 2003 Oct 23;46(22):4702-13.

PMID:
14561090
27.

Bibliography of resources by and about André Hellegers.

Goldstein DM.

Kennedy Inst Ethics J. 1999 Mar;9(1):89-107. No abstract available.

PMID:
11657317
28.

Functioning and well-being of patients in a consultation-liaison psychiatry clinic.

Epstein SA, Gonzales JJ, Stockton P, Goldstein DM, Green BL.

Gen Hosp Psychiatry. 1996 Jan;18(1):3-7.

PMID:
8666211
29.

Further ethics resources.

Goldstein DM.

Ann Intern Med. 1995 Apr 1;122(7):557. No abstract available.

PMID:
7872597
30.

Rejuvenating bioethics: literature and interpretive openness.

Goldstein DM.

Humane Med. 1994 Oct;10(4):275-81. No abstract available.

PMID:
11653135
31.

AIDS and women in Brazil: the emerging problem.

Goldstein DM.

Soc Sci Med. 1994 Oct;39(7):919-29.

PMID:
7992125
32.

Nursing ethics: a selected bibliography, 1987 to present.

Goldstein DM.

Kennedy Inst Ethics J. 1992 Jun;2(2):177-98. No abstract available.

PMID:
10119319
33.

Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease.

Liu YK, Goldstein DM, Arora K, Woo D, Ferris FZ, Marcum SG, Garrison RN, Amin M.

Surg Gynecol Obstet. 1991 Apr;172(4):269-74.

PMID:
2006450
34.

Borderline symptom inventory: assessing inpatient and outpatient borderline personality disorders.

Mann LS, Wise TN, Segall EA, Goldberg RL, Goldstein DM.

Psychopathology. 1988;21(1):44-50.

PMID:
3222432
35.

Monoamine oxidase inhibitor-induced speech blockage.

Goldstein DM, Goldberg RL.

J Clin Psychiatry. 1986 Dec;47(12):604.

PMID:
3782047
36.

Case report: psychosis with Stevens-Johnson syndrome and toxic epidermal necrolysis.

de Rego JA, Goldstein DM.

Hillside J Clin Psychiatry. 1985;7(2):141-8.

PMID:
4077031
37.

The acquisition of the diagonal concept.

Goldstein DM, Wicklund DA.

Child Dev. 1973 Mar;44(1):210-3. No abstract available.

PMID:
4706069
38.

An outbreak of polioencephalitis among Navy Cadets, possibly food borne.

GOLDSTEIN DM, HAMMON WM, VIETS HR.

J Am Med Assoc. 1946 Jun 15;131:569-73. No abstract available.

PMID:
20986019

Supplemental Content

Loading ...
Support Center